Search Within

Benjamin Heath Durham

  1. "Dermatology Service"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (9)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Dermatology (19)
  4. Dermatology Service (19)
  5. Division of Subspecialty Medicine (19)
  6. Hematologic Malignancies, Division of (19)

More Groups

People
  1. Eli Diamond (18)
  2. Mario Lacouture (18)
  3. Omar Abdel-Wahab (17)
  4. Raajit Rampal (12)
  5. Kseniya Petrova-Drus (11)
  6. Mariko Yabe (10)

More People

Years
  1. 2024 (2)
  2. 2023 (6)
  3. 2022 (1)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (3)

More Years

Publications
  1. Pediatric Blood and Cancer (5)
  2. Blood (4)
  3. British Journal of Haematology (2)
  4. Haematologica (2)
  5. Cancer Discovery (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. Wiley Periodicals, Inc (5)
  2. American Society of Hematology (4)
  3. Nature Publishing Group (3)
  4. Ferrata Storti Foundation (2)
  5. John Wiley & Sons (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
    Journal Article

    Krystel-Whittemore, M.; Petrova-Drus, K.; Ptashkin, R. N.; Ewalt, M. D.; Yao, J.; Liu, Y.; Zhu, M.; Benhamida, J.; Durham, B.; Kumar, J.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
    Journal Article

    Friedman, J. S.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Dogan, A.; Pulitzer, M.; Busam, K. J.; Francis, J. H.; Rampal, R. K.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society
    Meeting Abstract

    Goyal, G.; Acosta Medina, A. A.; Cao, X.; Bossert, D.; Matthew, P. C.; Makras, P.; Abdel-Wahab, O.; Abeykoon, J. P.; Amerikanou, R.; Bach, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • CSF1R inhibition for histiocytic neoplasm with CBL mutations refractory to MEK1/2 inhibition
    Research Letter

    Diamond, E. L.; Francis, J. H.; Lacouture, M. E.; Rotemberg, V.; Yabe, M.; Petrova-Drus, K.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H.
    Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Reiner, A. S.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Ulaner, G. A.; Reddy, R.; Lacouture, M. E.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Novel alterations in CSF1R, RET, and other diverse kinases in the histiocytoses with biochemical and structural insights into their mechanisms of activation
    Meeting Abstract

    Durham, B.; Lopez-Rodrigo, E.; Picarsic, J.; Abramson, D.; Rotemberg, V.; De Munck, S.; Pannecoucke, E.; Lu, S.; Pastore, A.; Mandelker, D.; more...
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save